{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T23:18:14Z","timestamp":1763767094411},"reference-count":29,"publisher":"Pharmaceutical Society of Japan","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2021,5,1]]},"DOI":"10.1248\/bpb.b21-00024","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T22:06:17Z","timestamp":1614377177000},"page":"707-713","source":"Crossref","is-referenced-by-count":6,"title":["Effects of the L\/N-Type Ca&lt;sup&gt;2+&lt;\/sup&gt; Channel Blocker Cilnidipine on the Cardiac Histological Remodelling and Inducibility of Atrial Fibrillation in High-Salt-Fed Rats"],"prefix":"10.1248","volume":"44","author":[{"given":"Eri","family":"Harada","sequence":"first","affiliation":[{"name":"Ajinomoto Pharmaceuticals Co., Ltd."},{"name":"Ajinomoto Co., Inc."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumi","family":"Sugino","sequence":"additional","affiliation":[{"name":"Ajinomoto Pharmaceuticals Co., Ltd."},{"name":"Ajinomoto Co., Inc."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Aimoto","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Faculty of Pharmaceutical Sciences, Toho University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Takahara","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Faculty of Pharmaceutical Sciences, Toho University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Ibaraki A, Goto W, Iura R, Tominaga M, Tsuchihashi T. Current prescription status of antihypertensive drugs with special reference to the use of diuretics in Japan. <i>Hypertens. Res.<\/i>, <b>40<\/b>, 203\u2013206 (2017).","DOI":"10.1038\/hr.2016.120"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Ferdinand KC, Nasser SA. Management of essential hypertension. <i>Cardiol. Clin.<\/i>, <b>35<\/b>, 231\u2013246 (2017).","DOI":"10.1016\/j.ccl.2016.12.005"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Caballero-Gonzalez FJ. Calcium channel blockers in the management of hypertension in the elderly. <i>Cardiovasc. Hematol. Agents Med. Chem.<\/i>, <b>12<\/b>, 160\u2013165 (2015).","DOI":"10.2174\/1871525713666150310111554"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Uneyama H, Takahara A, Dohmoto H, Yoshimoto R, Inoue K, Akaike N. Blockade of N-type Ca<sup>2+<\/sup> current by cilnidipine (FRC-8653) in acutely dissociated rat sympathetic neurones. <i>Br. J. Pharmacol.<\/i>, <b>122<\/b>, 37\u201342 (1997).","DOI":"10.1038\/sj.bjp.0701342"},{"key":"5","unstructured":"5) Takahara A. Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release. <i>Cardiovasc. Ther.<\/i>, <b>27<\/b>, 124\u2013139 (2009)."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Konda T, Enomoto A, Matsushita J, Takahara A, Moriyama T. The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome. <i>Nephron Physiol.<\/i>, <b>101<\/b>, 1\u201313 (2005).","DOI":"10.1159\/000085713"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Konda T, Enomoto A, Takahara A, Yamamoto H. Effects of L\/N-type calcium channel antagonist, cilnidipine on progressive renal injuries in Dahl salt-sensitive rats. <i>Biol. Pharm. Bull.<\/i>, <b>29<\/b>, 933\u2013937 (2006).","DOI":"10.1248\/bpb.29.933"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Aritomi S, Harada E, Sugino K, Nishimura M, Nakamura T, Takahara A. Comparison of the cardioprotective and renoprotective effects of the L\/N-type calcium channel blocker, cilnidipine, in adriamycin-treated spontaneously-hypertensive rats. <i>Clin. Exp. Pharmacol. Physiol.<\/i>, <b>42<\/b>, 344\u2013352 (2015).","DOI":"10.1111\/1440-1681.12360"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Takatsu M, Hattori T, Murase T, Ohtake M, Kato M, Nashima K, Nakashima C, Takahashi K, Ito H, Niinuma K, Aritomi S, Murohara T, Nagata K. Comparison of the effects of cilnidipine and amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats. <i>J. Hypertens.<\/i>, <b>30<\/b>, 1845\u20131855 (2012).","DOI":"10.1097\/HJH.0b013e3283567645"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Takai S, Jin D, Aritomi S, Niinuma K, Miyazaki M. Powerful vascular protection by combining cilnidipine with valsartan in stroke-prone, spontaneously hypertensive rats. <i>Hypertens. Res.<\/i>, <b>36<\/b>, 342\u2013348 (2013).","DOI":"10.1038\/hr.2012.187"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Takahara A, Nakamura Y, Wagatsuma H, Aritomi S, Nakayama A, Satoh Y, Akie Y, Sugiyama A. Long-term blockade of L\/N-type Ca(2+) channels by cilnidipine ameliorates repolarization abnormality of the canine hypertrophied heart. <i>Br. J. Pharmacol.<\/i>, <b>158<\/b>, 1366\u20131374 (2009).","DOI":"10.1111\/j.1476-5381.2009.00407.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Mori Y, Aritomi S, Niinuma K, Nakamura T, Matsuura K, Yokoyama J, Utsunomiya K. Additive effects of cilnidipine, an L-\/N-type calcium channel blocker, and an angiotensin II receptor blocker on reducing cardiorenal damage in Otsuka Long-Evans Tokushima Fatty rats with type 2 diabetes mellitus. <i>Drug Des. Devel. Ther.<\/i>, <b>8<\/b>, 799\u2013810 (2014).","DOI":"10.2147\/DDDT.S47441"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Aritomi S, Niinuma K, Ogawa T, Konda T, Nitta K. Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats. <i>Clin. Exp. Nephrol.<\/i>, <b>17<\/b>, 41\u201350 (2013).","DOI":"10.1007\/s10157-012-0677-4"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Aritomi S, Koganei H, Wagatsuma H, Mitsui A, Ogawa T, Nitta K, Konda T. The N-type and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-salt diet. <i>Heart Vessels<\/i>, <b>25<\/b>, 549\u2013555 (2010).","DOI":"10.1007\/s00380-010-0005-4"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Zimetbaum P. Atrial Fibrillation. <i>Ann. Intern. Med.<\/i>, <b>166<\/b>, ITC33\u2013ITC48 (2017).","DOI":"10.7326\/AITC201703070"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, Merkely B, Pokushalov E, Sanders P, Proff J, Schunkert H, Christ H, Vogt J, Bansch D. Catheter ablation for atrial fibrillation with heart failure. <i>N. Engl. J. Med.<\/i>, <b>378<\/b>, 417\u2013427 (2018).","DOI":"10.1056\/NEJMoa1707855"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Solun B, Marcoviciu D, Dicker D. Does treatment of hypertension decrease the incidence of atrial fibrillation and cardioembolic stroke? <i>Eur. J. Intern. Med.<\/i>, <b>20<\/b>, 125\u2013131 (2009).","DOI":"10.1016\/j.ejim.2008.07.001"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Turin A, Bax JJ, Doukas D, Joyce C, Lopez JJ, Mathew V, Pontone G, Shah F, Singh S, Wilber DJ, Rabbat MG. Interactions among vitamin D, atrial fibrillation, and the renin\u2013angiotensin\u2013aldosterone system. <i>Am. J. Cardiol.<\/i>, <b>122<\/b>, 780\u2013784 (2018).","DOI":"10.1016\/j.amjcard.2018.05.013"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Nattel S. Molecular and cellular mechanisms of atrial fibrosis in atrial fibrillation. <i>JACC Clin. Electrophysiol.<\/i>, <b>3<\/b>, 425\u2013435 (2017).","DOI":"10.1016\/j.jacep.2017.03.002"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Corradi D, Callegari S, Maestri R, Benussi S, Alfieri O. Structural remodeling in atrial fibrillation. <i>Nat. Clin. Pract. Cardiovasc. Med.<\/i>, <b>5<\/b>, 782\u2013796 (2008).","DOI":"10.1038\/ncpcardio1370"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Burstein B, Nattel S. Atrial structural remodeling as an antiarrhythmic target. <i>J. Cardiovasc. Pharmacol.<\/i>, <b>52<\/b>, 4\u201310 (2008).","DOI":"10.1097\/FJC.0b013e3181668057"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Hunyady L, Catt KJ. Pleiotropic AT<sub>1<\/sub> receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. <i>Mol. Endocrinol.<\/i>, <b>20<\/b>, 953\u2013970 (2006).","DOI":"10.1210\/me.2004-0536"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Xiao HD, Fuchs S, Campbell DJ, Lewis W, Dudley SC Jr, Kasi VS, Hoit BD, Keshelava G, Zhao H, Capecchi MR, Bernstein KE. Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. <i>Am. J. Pathol.<\/i>, <b>165<\/b>, 1019\u20131032 (2004).","DOI":"10.1016\/S0002-9440(10)63363-9"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Nagasawa K, Takahashi K, Matsuura N, Takatsu M, Hattori T, Watanabe S, Harada E, Niinuma K, Murohara T, Nagata K. Comparative effects of valsartan in combination with cilnidipine or amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats. <i>Hypertens. Res.<\/i>, <b>38<\/b>, 39\u201347 (2015).","DOI":"10.1038\/hr.2014.136"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Aritomi S, Niinuma K, Kawakami M, Nakamura T, Konda T, Shiozaki M, Yoshimura M. Cilnidipine, an L-\/N-type calcium channel blocker, changes the circulating angiotensin\u2013(1\u20137)\/Angiotensin II Ratio. <i>J. Hypertens. Open Access<\/i>, <b>1<\/b>, 102 (2012).","DOI":"10.4172\/2167-1095.1000102"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Nishimura A, Shimauchi T, Tanaka T, Shimoda K, Toyama T, Kitajima N, Ishikawa T, Shindo N, Numaga-Tomita T, Yasuda S, Sato Y, Kuwahara K, Kumagai Y, Akaike T, Ide T, Ojida A, Mori Y, Nishida M. Hypoxia-induced interaction of filamin with Drp1 causes mitochondrial hyperfission-associated myocardial senescence. <i>Sci. Signal.<\/i>, <b>11<\/b>, eaat5185 (2018).","DOI":"10.1126\/scisignal.aat5185"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. <i>Circulation<\/i>, <b>92<\/b>, 1954\u20131968 (1995).","DOI":"10.1161\/01.CIR.92.7.1954"},{"key":"28","unstructured":"28) Wijffels MC, Kirchhof CJ, Dorland R, Power J, Allessie MA. Electrical remodeling due to atrial fibrillation in chronically instrumented conscious goats: roles of neurohumoral changes, ischemia, atrial stretch, and high rate of electrical activation. <i>Circulation<\/i>, <b>96<\/b>, 3710\u20133720 (1997)."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Tajiri K, Guichard JB, Qi X, Xiong F, Naud P, Tardif JC, Costa AD, Aonuma K, Nattel S. An N-\/L-type calcium channel blocker, cilnidipine, suppresses autonomic, electrical, and structural remodelling associated with atrial fibrillation. <i>Cardiovasc. Res.<\/i>, <b>115<\/b>, 1975\u20131985 (2019).","DOI":"10.1093\/cvr\/cvz136"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/5\/44_b21-00024\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T03:39:16Z","timestamp":1619840356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/5\/44_b21-00024\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b21-00024","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,1]]}}}